Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTCT vs IONS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTCT Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

PTCT Overall Winner 6-Pillar Tally: PTCT 4 – 2 IONS Matrix Metrics: PTCT 8 – 2 IONS

As of Nov 16, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTCT carries a Unified Composite Score of 45.4/100 (HOLD) at $61.61 (19.9x Forward P/E, 21.5% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.75 (90.9x Forward P/E, -58.8% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTCT 45.4/100 HOLD), PTCT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. -58.8% operating margin) and revenue trajectory (+69.6% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: PTCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTCT vs IONS
PTCT NASDAQ Head-to-Head Winner
PTC Therapeutics, Inc.
Pharmaceutical Preparations
$61.61
-2.96% 1D
Market Cap $5.3B
TTM Revenue $1.16B
Forward P/E 19.9x
Beta / 30D Vol 0.82β · 58% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 48.0 Fund 54.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $63.57 · SMA50: $63.96
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.75
-1.08% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07

6-Pillar Scorecard Institutional Category Breakdown (PTCT 4 – 2 IONS)

Columns: Metric · PTCT · IONS
1. Valuation Multiples PTCT
Forward P/E 19.9x 90.9x
Trailing P/E 19.4x 90.9x
PEG Ratio 0.81x N/M
EV / Revenue 4.7x 6.2x
2. Growth & Scale PTCT
Revenue Growth (YoY) +69.6% +54.9%
Earnings Growth (YoY) +0.0% -43.7%
TTM Revenue (USD) $1.16B $960M
Market Cap $5.3B $4.7B
3. Profitability & Quality PTCT
Gross Margin 55.2% 3.0%
Operating Margin 21.5% -58.8%
Net Profit Margin -9.2% -56.9%
Return on Equity (ROE) -7740.1% -108.0%
4. Balance Sheet & Cash Flow PTCT
Cash Generation (TTM) -$41M -$623M
Cash Flow Margin -3.6% -64.9%
Net Cash / Leverage $127M Net Debt $1.33B Net Debt (4.14x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IONS
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 55.7% (17th %ile) 59.9% (17th %ile)
Put/Call OI Skew 0.18x (Call-Skewed) 1.81x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 33.7% of Rev ($389M) 61.8% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTCT (8) vs IONS (2)
Institutional Metric PTCT IONS Criterion Row Edge
Market Capitalization
Scale
$5.3B $4.7B Larger Scale PTCT
Trailing P/E Ratio
Valuation
19.4x 90.9x Lower Multiple PTCT
Forward P/E Ratio
Valuation
19.9x 90.9x Lower Multiple PTCT
Revenue Growth (YoY)
Growth
+69.6% +54.9% Higher Growth PTCT
Operating Margin (TTM)
Profitability
21.5% -58.8% Higher Margin PTCT
Net Profit Margin
Profitability
-9.2% -56.9% Higher Margin PTCT
Return on Equity (ROE)
Capital Efficiency
-7740.1% -108.0% Higher ROE IONS
52-Week Range Position
Momentum
9% ($59–$91) 2% ($27–$87) Stronger Trend PTCT
Beta / 30D Volatility
Risk Regime
0.82β · 58% Vol 0.18β · 86% Vol Lower Realized Risk PTCT
Unified Institutional Score
Composite Signal
45.4 / 100 (HOLD) 63.9 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$1.16B $960M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
55.2% 3.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.81x PEG · 4.7x EV/Rev N/M PEG · 6.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($127M Net Debt) -$623M ($1.33B Net Debt (4.14x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTCT +37.06 pp
PTCT: +4.0% · IONS: -33.06%
3M Horizon PTCT +36.62 pp
PTCT: -15.17% · IONS: -51.79%
6M Horizon PTCT +48.19 pp
PTCT: -12.17% · IONS: -60.36%
1Y Horizon PTCT +41.04 pp
PTCT: -17.8% · IONS: -58.84%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PTCT Revenue IONS Revenue PTCT Op. Margin IONS Op. Margin Margin Leader
FY2018 $260M $600M -43.7% -10.2% IONS
FY2019 $310M $1.12B -78.6% 32.6% IONS
FY2020 $380M $730M -113.4% -23.6% IONS
FY2021 $540M $810M -69.5% -3.7% IONS
FY2022 $700M $590M -64.0% -69.8% PTCT
FY2023 $940M $790M -46.9% -44.9% IONS
FY2024 $810M $710M -37.5% -67.4% PTCT
FY2025 $1.73B $940M 50.1% -40.4% PTCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTCT BREAKDOWN
91d in phase · OBV DISTRIBUTION
Current IV 55.7%
IV Percentile 17th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact PTCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTCT Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 21.5% operating margin.
OpEx & R&D Reinvestment 33.7% of Rev ($389M)
90D Engineering Disclosures 0 Published
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ PTCT vs IONS Key Questions & Quantitative Answers

As of Nov 16, 2026, PTC Therapeutics, Inc. (PTCT) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PTCT carries a Unified Composite Score of 45.4/100 (HOLD) at $61.61 (19.9x Forward P/E, 21.5% operating margin), whereas IONS carries 63.9/100 (BUY) at $28.75 (90.9x Forward P/E, -58.8% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTCT 45.4/100 HOLD), PTCT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (21.5% vs. -58.8% operating margin) and revenue trajectory (+69.6% vs. +54.9% YoY). Technical & Structure Timing Caution: PTCT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1); meanwhile IONS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTCT leads the Growth & Scale pillar: PTCT posts +69.6% YoY revenue growth and +0.0% YoY earnings growth on $1.16B TTM revenue (55.2% gross margin, 21.5% operating margin), compared with IONS at +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PTCT cumulative revenue shifted +565.4% while IONS shifted +56.7%. In operating R&D and SG&A reinvestment, PTCT deploys 33.7% of Rev ($389M) (0 90-day corporate R&D disclosures) versus 61.8% of Rev ($593M) (0 disclosures) for IONS.

PTCT screens cheaper on headline valuation multiples. PTCT trades at 19.9x Forward P/E, 19.4x Trailing P/E, 0.81x PEG, and 4.7x EV/Revenue (-3.6% FCF margin), whereas IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTCT (-7740.1% ROE) versus IONS (-108.0% ROE) capital efficiency.

In options market volatility and institutional positioning, PTCT carries 55.7% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.82β · 58% Vol realized risk). By comparison, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.